Friday, December 21, 2012

Brodalumab at the ACR 2012 in Washington

More on brodalumab and the EULAR 2013 at:

Brodalumab targets interleukin-17 (IL-17) and is therefore much like ixekizumab, which hasn’t been presented at the 2012 ACR meeting. Ixekizumab is studied in chronic plaque psoriasis as shown in this article of the New England Journal of Medicine: Back to brodalumab.

Karel Pavelka and collaegues looked at safety, tolerability, and efficacy of brodalumab (AMG 827) in rheumatoid arthritis and an inadequate response to Methotrexate (Abstract No. 831), but the preliminary results do not support further evaluation of brodalumab as a treatment for RA.

M.A. Curchill and collaegues presented "A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis" (Abstract No. 1294). “Conclusions about efficacy cannot be reached given the study design.”

I think brodalumab is a dead end for rheumatoid arthritis though it might be useful in other diseases.


  1. Yes! Finally someone writes about cara menambahkan file ke cd yang sudah ada isinya.

    1. cara menambahkan file ke cd yang sudah ada isinya
      is Indonesian for:
      how to add files to the existing cd content.

      I wonder about the reason to get this comment posted.